Clear Labelling Of Industrial & Medical Oxygen Must, PMO Tells Health Ministry

New Delhi:  The Prime Minister’s Office (PMO) has written to the health ministry to take necessary action regarding the labelling of oxygen cylinders to differentiate between industrial and medical oxygen after lawmaker Ajeet Madhavrao Gopchade raised the need to do so in the interest of patients.

“I brought this to the notice of the PMO. As a doctor, I understand it is a critical issue and needs attention. To protect patients, even the World Health Organization has released guidelines on the quality of medical oxygen,” Gopchade told ET.

“Throughout the Covid pandemic, it was noted that a significant number of patients who needed external oxygen support acquired a fungal infection. Unfortunately, many individuals lost their eyesight as a result. There seems to be a lack of focus from the state and central government on guaranteeing the quality of medical oxygen. There is a shortage of clear labelling on oxygen cylinders to differentiate between industrial and medical oxygen,” the lawmaker said in his letter to the PMO.

He urged the PMO to instruct the relevant authorities to issue advisory to state governments directing them to ensure the quality of medical oxygen and conduct mandatory inspections of medical oxygen production facilities.

Taking cognizance of the issue, the PMO has written to the health ministry directing it “to take action as deemed appropriate”.

In India, the Ministry of Health and Family Welfare (MoHFW) and the Department for Promotion of Industry and Internal Trade (DPIIT) are responsible for managing the supply of medical oxygen in India. While the health ministry develops guidelines for setting up oxygen plants, DPIIT manages the supply of medical oxygen, including drugs and equipment.

Different industries, including health systems, use oxygen on a regular basis. According to the WHO, medical-use oxygen is very different from industrial oxygen in purity and quality. “Thus, industrial and medical use (oxygen) are not interchangeable,” says the WHO document.

Related Posts

Eli Lilly launches cancer drug Tanstrive in India

New Delhi: Eli Lilly and Company India on Thursday announced the launch of its cancer treatment drug Tanstrive in India. The launch follows marketing authorisation from the Central Drugs Standard Control Organisation…

Centre eases BIS quality compliance with new risk-based framework for manufacturers

The Centre has introduced a risk-based compliance mechanism to ease industry compliance with Quality Control Orders (QCOs), allowing eligible manufacturers to follow a simplified certification route while maintaining product quality…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Eli Lilly launches cancer drug Tanstrive in India

Eli Lilly launches cancer drug Tanstrive in India

Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

Centre eases BIS quality compliance with new risk-based framework for manufacturers

Centre eases BIS quality compliance with new risk-based framework for manufacturers

SS Innovations International aces Race beating Global Giants in Surgical Robotics

SS Innovations International aces Race beating Global Giants in Surgical Robotics

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

India curbs supply of IVF consumables to unregistered clinics

India curbs supply of IVF consumables to unregistered clinics